Trials / Active Not Recruiting
Active Not RecruitingNCT07020923
Monthly Dosing of Atacicept in IgAN
A Study Evaluating Monthly (Every 4 Weeks) Dosing of Atacicept in Patients With IgAN
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- Sponsor
- Vera Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2, open-label, multicenter, randomized study comprising parallel groups of participants receiving weekly and/or monthly doses of atacicept
Detailed description
This Phase 2 study is to explore the effectiveness, safety and tolerability of different dosing regimens of atacicept. Regimens include monthly and weekly dosing.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atacicept | Drug: Atacicept |
Timeline
- Start date
- 2025-05-29
- Primary completion
- 2026-09-01
- Completion
- 2027-09-01
- First posted
- 2025-06-13
- Last updated
- 2026-04-13
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07020923. Inclusion in this directory is not an endorsement.